Travere Therapeutics, Inc. TVTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $127.2M+55.6% | $129.69M+73.4% | $164.86M+162% | $114.45M+111% | $81.73M+97.5% | ||
| $1.95M-58.3% | $2.55M0.0% | $1.59M-2.5% | $1.52M-26.2% | $4.68M+211% | ||
| $125.25M+62.5% | $127.14M+76.0% | $163.27M+166% | $112.93M+117% | $77.05M+93.3% | ||
| 98.5%+4.2pp | 98%+1.4pp | 99%+1.6pp | 98.7%+2.5pp | 94.3%-2.1pp | ||
| $57.09M+21.8% | $57.87M-6.8% | $51.89M+0.4% | $49.36M-9.1% | $46.89M-5.1% | ||
| $80.25M+32.8% | $101.69M+46.3% | $86.45M+31.7% | $76.22M+17.7% | $60.41M-5.9% | ||
| $164.11M+31.9% | $162.12M+19.6% | $139.93M+17.5% | $127.1M+4.3% | $124.41M-31.1% | ||
| -$36.92M+13.5% | -$32.43M+46.6% | $24.93M+144% | -$12.65M+81.3% | -$42.67M+69.4% | ||
| -29%+23.2pp | -25%+56.2pp | 15.1%+104pp | -11.1%+114pp | -52.2%+284pp | ||
| $2.3M-19.5% | $2.3M-18.5% | $2.75M-0.9% | $2.85M+2.1% | $2.86M+2.0% | ||
| $193K-87.0% | $11.36M+2,762% | $783K-40.4% | -$85K+95.4% | $1.49M-57.1% | ||
| -$36.72M+10.8% | -$21.07M+65.1% | $25.71M+147% | -$12.74M+81.7% | -$41.19M+69.7% | ||
| -$120K-408% | $921K— | $8K+110% | $20K-76.5% | $39K-79.6% | ||
| -$37.1M+10.0% | —— | $25.71M+147% | -$12.76M+81.9% | -$41.23M+69.7% | ||
| -29.2%+21.3pp | —— | 15.6%+103pp | -11.1%+119pp | -50.4%+278pp | ||
| -$0.40+14.9% | —— | $0.28+140% | -$0.14+84.6% | -$0.47+73.3% | ||
| -$11.7M+60.8% | -$14.29M+70.6% | $40.72M+191% | $1.37M+102% | -$29.87M+76.9% | ||
| -9.2%+27.3pp | -11%+54.0pp | 24.7%+96.1pp | 1.2%+107pp | -36.5%+276pp | ||
| -$36.92M+13.5% | -$32.43M+46.6% | $24.93M+144% | -$12.65M+81.3% | -$42.67M+69.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Travere Therapeutics, Inc.'s revenue?
- Travere Therapeutics, Inc. (TVTX) generated $536.2M in revenue over the trailing twelve months, up 96.0% year over year.
- Is Travere Therapeutics, Inc. profitable?
- Travere Therapeutics, Inc. is not currently profitable: it reported a net loss of $65.4M over the trailing twelve months, a -20.3% net margin.
- What are Travere Therapeutics, Inc.'s profit margins?
- Gross margin is 98.6% and operating margin is -10.6%, with a -20.3% net margin.
- What is Travere Therapeutics, Inc.'s earnings per share?
- Travere Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.73.
- Where does Travere Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
